Diwali Muhurat Trading 2025: Cipla Hits 52-Week High Ahead of Q2 Results; Pharma Stock Up Nearly 2%

Shares of pharmaceutical major Cipla Ltd rose nearly 2% on Tuesday, touching a one-year high of Rs 1,669 apiece during the special Muhurat Trading session on Diwali. The stock emerged as a top gainer in the Nifty 50 index, buoyed by strong investor confidence ahead of its Q2 earnings announcement and robust performance in previous quarters.

Diwali Muhurat Trading 2025 Samvat 2082: Cipla Share Price Today

On October 21, 2025, shares of Cipla Ltd were trading at Rs 1,665.00, up by Rs 25.90 or 1.58% as of 2:45 PM during the Muhurat trading session. The stock opened the day at Rs 1,646.70 and hit an intraday high of Rs 1,669.00, which also marks its new 52-week high. The day's low stood at Rs 1,642.10.

Cipla's 52-week trading range now stands between Rs 1,335.00 and Rs 1,669.00, indicating strong bullish momentum in recent weeks.

Over the last five trading sessions, Cipla shares have gained almost 7%, while the monthly gain stands at 8%. In the past six months, the stock has rallied over 20%, and it has recorded a 9% increase since the beginning of 2025. The company's market capitalisation currently stands at approximately Rs 1.35 lakh crore, reflecting its strong position in the Indian pharmaceutical sector.

Cipla Q2 Results Date Announced; Check Date

Cipla has notified stock exchanges that its board of directors will meet on October 30, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. Investors are keenly watching for this update, especially in light of the company's consistent performance across geographies and segments.

Cipla's Performance in Q1 FY26

In the first quarter of the current financial year, Cipla reported a 10% year-on-year (YoY) growth in its consolidated net profit, which rose to ₹1,298 crore, compared to ₹1,178 crore in the same quarter of the previous fiscal.

The company's total revenue from operations came in at ₹6,957 crore, reflecting a 4% YoY increase from ₹6,694 crore. Operating profit (EBITDA) stood at ₹1,778 crore, up by 3.6% from ₹1,716 crore last year. The EBITDA margin remained steady at 25.6%, maintaining profitability despite sectoral challenges.

Cipla's Strong Growth in India and Overseas Markets

Cipla's One India business reported a 6% YoY growth, surpassing the Rs 3,000 crore revenue mark for the first time in the opening quarter of any fiscal year. This growth was driven by continued strength in prescription, consumer health, and trade generics segments.

In the US market, Cipla delivered quarterly revenues of $226 million, supported by solid performance in differentiated assets and consistent growth in its respiratory and complex generics portfolio.

The company's Africa operations continued their positive trajectory with 11% revenue growth YoY in dollar terms, while emerging markets and Europe also posted 8% YoY revenue growth, underscoring Cipla's global footprint.

Cipla's commitment to innovation remained evident, with research and development (R&D) expenses reaching Rs 432 crore, representing 6.2% of sales.